Mckesson
MCK
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$20.6m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$755.60
-12.7% in the quarter
Share price change by quarter
-15.3%Q3 ’24
+15.3%Q4 ’24
+18.1%Q1 ’25
+8.9%Q2 ’25
+5.4%Q3 ’25
+6.2%Q4 ’25
+5.5%Q1 ’26
-12.7%Q2 ’26
Managers holding it, by quarter
1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Who holds it
| Muhlenkamp & Company | 6.0%$20.6m | Added +0.1% |
Directors buying and selling
How this works
| Bought or sold | ||||
|---|---|---|---|---|
| 15 Oct 2026 | Fraga FranciscoEVP, CIO and CTO | ▼ Sold | 800.491 | $797k |
| 8 Sep 2026 | Rutledge Napoleon B JrSVP, Controller & CAO | ▼ Sold | 111 | $99k |
| 10 Aug 2026 | Lerman Bradley EDirector | ▼ Sold | 301 | $269k |
About the company
- Sector
- Health care · Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- Delaware
- Financial year ends
- 31 March
- Shares outstanding
- 117m at 31 Jul 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$137bnMar ’14
$191bnMar ’16
$208bnMar ’18
$231bnMar ’20
$264bnMar ’22
$309bnMar ’24
$403bnMar ’26
| Year | Revenue | Net income |
|---|---|---|
| Year to Mar 2026 | $403bn | $4.8bn |
| Year to Mar 2025 | $359bn | $3.3bn |
| Year to Mar 2024 | $309bn | $3.0bn |
| Year to Mar 2023 | $277bn | $3.6bn |
| Year to Mar 2022 | $264bn | $1.1bn |
| Year to Mar 2021 | $238bn | −$4.5bn |
| Year to Mar 2020 | $231bn | $900m |
| Year to Mar 2019 | $214bn | $34.0m |
| Year to Mar 2018 | $208bn | $67.0m |
| Year to Mar 2017 | $199bn | $5.1bn |
| Year to Mar 2016 | $191bn | $2.3bn |
| Year to Mar 2015 | $179bn | $1.5bn |
| Year to Mar 2014 | $137bn | $1.3bn |
In fund portfolios
| Muhlenkamp FundMuhlenkamp & Company | 4.8% |